Editorial Material
Gastroenterology & Hepatology
Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim
Summary: The review highlights the crucial role of gut microbes in maintaining liver homeostasis and the impact of dysbiosis on the development of fatty liver disease. The changes in gut microbial composition in alcoholic and nonalcoholic fatty liver diseases and how they contribute to the pathophysiology of the disease are discussed. New approaches related to gut microbes for the diagnosis and treatment of fatty liver disease are also summarized.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Maria Del Barrio, Lucia Lavin, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Aitor Odriozola, Juan Carlos Rodriguez-Duque, Coral Rivas, Paula Iruzubieta, Javier Crespo
Summary: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) currently. Lifestyle change is the only available therapeutic recommendation, but adherence to this approach is often challenging. Manipulation of the microbiota and improving intestinal permeability may offer promising therapeutic strategies for NAFLD. Faecal microbiota transplantation (FMT) is a potential method to achieve this. In this review, we summarize key aspects of FMT, discuss its current indications, and highlight recent advances in NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Physiology
Dongqing Wu, Huaqing Zhu, Hua Wang
Summary: The liver, as the largest vital solid organ in the body, consists of multiple types of cells that communicate critically to maintain liver function homeostasis. Extracellular vesicles (EVs) play a significant role in cell-to-cell communication and are involved in the development of liver diseases.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Health Care Sciences & Services
Laura Valenzuela-Vallejo, Despina Sanoudou, Christos S. Mantzoros
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with various complications. The lack of non-invasive diagnosis and effective treatment calls for a more specific subcategorization of fatty liver disease (FLD). A precision medicine approach based on subcategorization is expected to improve patient care and reduce healthcare costs associated with FLD.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Daniela Stols-Goncalves, Anne Linde Mak, Mette S. Madsen, Eduard W. J. van der Vossen, Eveline Bruinstroop, Peter Henneman, Femke Mol, Torsten P. M. Scheithauer, Loek Smits, Julia Witjes, Abraham Stijn Meijnikman, Joanne Verheij, Max Nieuwdorp, Adriaan G. Holleboom, Evgeni Levin
Summary: Individuals with NAFLD underwent FMT intervention to investigate the relationship between gut microbiota composition, liver DNA methylation, and plasma metabolite profiles. The study found that FMT induced differential changes in gut microbiota profiles, plasma metabolites, and hepatic DNA methylation profiles in NAFLD patients. The results suggest that FMTs can cause metaorganismal pathway changes from the gut bacteria to the liver.
Review
Cell Biology
Daryl Ramai, Antonio Facciorusso, Erika Vigandt, Bryan Schaf, Waleed Saadedeen, Aditya Chauhan, Sara di Nunzio, Aashni Shah, Luca Giacomelli, Rodolfo Sacco
Summary: NASH is a chronic and progressive form of non-alcoholic fatty liver disease with increasing global incidence, posing an epidemic and public health threat. The disease is associated with major morbidity and mortality, with patients at risk of developing hepatocellular carcinoma. Current evidence suggests a multi-hit model involving various pathways leading to progressive fibrosis and oncogenesis, highlighting the complexity of the disease.
Article
Biochemistry & Molecular Biology
Marcin Kosmalski, Jozef Drzewoski, Izabela Szymczak-Pajor, Andrzej Zieleniak, Melania Mikolajczyk-Solinska, Jacek Kasznicki, Agnieszka Sliwinska
Summary: The study aimed to evaluate the association between Irisin and non-alcoholic fatty liver disease (NAFLD). The results showed that Irisin concentration was correlated with anthropometric and biochemical parameters, suggesting its potential as a diagnostic biomarker for NAFLD.
Letter
Gastroenterology & Hepatology
Hui-Chin Chang, Shuo-Yan Gau
Summary: This article is associated with Park et al papers. To access and view these articles, please visit.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Medicine, General & Internal
Guanlin Li, Xinrong Zhang, Huapeng Lin, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Summary: New developments in non-invasive assessment methods show potential in diagnosing and monitoring NAFLD. Magnetic resonance imaging and blood biomarkers can be used to detect hepatic steatosis and fibrosis, but further research is needed to confirm their role in treatment monitoring.
CHINESE MEDICAL JOURNAL
(2022)
Review
Biochemistry & Molecular Biology
Ji-Won Park, Sung-Eun Kim, Na Young Lee, Jung-Hee Kim, Jang-Han Jung, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Dong-Joon Kim, Hyoung-Su Kim, Ki Tae Suk
Summary: Chronic liver disease, including alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), is influenced by gut microbiota dysregulation through the gut-liver axis. The gut microbiota releases various metabolites that affect host immunity and metabolism, while the integrity of the intestinal barriers is crucial in protecting the liver from harmful substances. This review discusses the pathologic effects of gut microbiota-derived metabolites in the liver and presents recent advancements in molecular-based therapies and mechanistic findings related to the gut-liver axis in ALD and NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Aleksandra Hliwa, Bruno Ramos-Molina, Dariusz Laski, Adriana Mika, Tomasz Sledzinski
Summary: Non-alcoholic fatty liver disease (NAFLD) is a major global public health problem characterized by alterations in hepatic lipid metabolism that can lead to serious liver complications. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid changes in NAFLD patients, focusing on alterations in long-chain and short-chain fatty acids levels as well as the expression of genes encoding lipid interconversion enzymes in the liver.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Andrea Dalbeni, Marco Castelli, Mirko Zoncape, Pietro Minuz, David Sacerdoti
Summary: Non alcoholic steatohepatitis (NASH) is an inflammatory reaction of the liver caused by excessive accumulation of lipids in hepatocytes. It can lead to cirrhosis and hepatocellular carcinoma (HCC). Fatty liver is a manifestation of metabolic syndrome, which is associated with subclinical inflammation. Platelets are involved in immune response and activation of stellate cells, and may play a key role in the development of NASH. Antiplatelet drugs have been shown to interrupt this process and improve NASH and metabolic alterations.
FRONTIERS IN PHARMACOLOGY
(2022)